Immuneering extends Phase 2 pancreatic trial and accelerates Phase 3 enrollment
Immuneering reported Q3 2026 results, extending the Phase 2 PDAC trial follow-up and expanding the Phase 3 MAPKeeper 301 enrollment target to 570 patients, which may accelerate data to mid-2028. The company also projected a cash runway into Q4 2028.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed